Conexeu Sciences Inc. (NASDAQ:CNXU)
| Market Cap | 97.94M-72.0% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 26.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 327,847 |
| Open | 3.20 |
| Previous Close | 3.12 |
| Day's Range | 3.15 - 3.74 |
| 52-Week Range | 3.05 - 18.79 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | 20.00(+446.45%) |
| Earnings Date | n/a |
Insiders here have filed 4 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About CNXU
Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R. Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CNXU stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CNXU holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CNXU's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CNXU Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CNXU patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CNXU from public contracts
Source: USAspending.gov
CNXU Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CNXU’s recent data — informational, not investment advice
